Stay updated on Dupilumab in Pediatric Peanut Allergy Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in Pediatric Peanut Allergy Clinical Trial page.

Latest updates to the Dupilumab in Pediatric Peanut Allergy Clinical Trial page
- CheckyesterdayChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check8 days agoChange DetectedThe revision label in the footer changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedAccess to the study record is blocked by a 403 Forbidden page, replacing the page content with an error screen. This prevents viewing details such as study status, locations, contacts, and related information.SummaryDifference18%

- Check50 days agoChange DetectedAdded a note for NIH grant/contract funding in 2018 and updated the site revision to v3.6.6, replacing the previous v3.6.5.SummaryDifference0.1%

- Check72 days agoChange DetectedRevision: v3.6.5 is now displayed, replacing v3.6.4 on the page. This represents a minor version update to the page.SummaryDifference0.1%

- Check87 days agoChange DetectedA new publication citation is added to Publications for a 2025 Allergy study on dupilumab in pediatric peanut allergy, and the revision is updated to v3.6.4.SummaryDifference0.1%

Stay in the know with updates to Dupilumab in Pediatric Peanut Allergy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in Pediatric Peanut Allergy Clinical Trial page.